Simvastatin, an inhibitor of YAP1, can inhibit the biological activity of YAP, increase the sensitivity of CRC cells to EGFR inhibitors, and improve therapeutic efficacy (Lee et al., 2015). The gene discussed is YAP1; the disease is colorectal carcinoma.